+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Obstructive Pulmonary Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Chronic Obstructive Pulmonary Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Chronic Obstructive Pulmonary Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010864
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Obstructive Pulmonary Disease Therapeutics Market is projected to reach USD 25.16 Billion in 2026. It is expected to continue growing at a CAGR of 7.62%, reaching USD 39.16 Billion by 2032.

Chronic obstructive pulmonary disease (COPD) therapeutics are entering a higher-value phase as treatment moves beyond symptomatic bronchodilation toward phenotype-directed care, earlier intervention, and integrated disease management. COPD remains one of the world’s leading causes of death, with the World Health Organization identifying it as the third leading cause of mortality globally and attributing more than 3 million deaths to the disease in 2019.

Demand for COPD treatment is supported by aging populations, continued tobacco exposure, occupational risk, indoor and outdoor air pollution, and improved diagnosis through spirometry and primary-care screening. The therapeutic landscape is anchored by long-acting bronchodilators, inhaled corticosteroid combinations, phosphodiesterase inhibitors, antibiotics for exacerbation-prone patients, oxygen therapy, pulmonary rehabilitation, and smoking cessation, while recent approvals for novel anti-inflammatory and biologic options are expanding the addressable treated population.

Transformative Shifts in the COPD Treatment Landscape

The COPD therapeutics landscape is being reshaped by three structural shifts: precision phenotyping, escalation from dual to triple inhaled therapy, and renewed innovation in anti-inflammatory mechanisms. GOLD recommendations increasingly emphasize exacerbation history, symptom burden, blood eosinophil counts, inhaler technique, and comorbidity management, which is changing prescribing decisions across pulmonology and primary care.

Recent regulatory activity marks a turning point. The U.S. approval of ensifentrine in 2024 introduced a first-in-class inhaled PDE3/PDE4 therapy for maintenance COPD treatment, while biologic therapy for eosinophilic COPD has opened a new pathway for patients with persistent exacerbations despite optimized inhaled therapy. These advances are intensifying competition around differentiated mechanisms, real-world outcomes, device usability, and payer-recognized reductions in exacerbations and hospital utilization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the COPD therapeutics value chain. In drug discovery, AI models are used to screen inflammatory pathways, identify repurposing opportunities, optimize trial populations, and analyze multi-omics signals associated with exacerbation risk, eosinophilic inflammation, and treatment response.

In care delivery, AI-enabled spirometry interpretation, digital inhaler monitoring, remote symptom tracking, and predictive analytics can support earlier intervention before acute exacerbations. The cumulative impact is strongest where AI is paired with validated clinical workflows, transparent algorithms, privacy-compliant data governance, and reimbursement models that reward reduced emergency visits, fewer hospitalizations, and better medication adherence.

Key Regional Insights

North America remains a leading region for COPD therapeutics due to high diagnosis rates, advanced reimbursement infrastructure, strong specialty care networks, and rapid adoption of novel inhaled and biologic therapies. The United States drives clinical trial activity and commercial uptake, while Canada emphasizes guideline-led prescribing, smoking cessation, vaccination, pulmonary rehabilitation, and access through public and private coverage pathways.

Europe benefits from established respiratory care systems, the European Respiratory Society’s influence, and broad use of maintenance inhalers across major markets, although pricing, environmental inhaler policies, and health technology assessment requirements shape launch strategies. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia confront large COPD burdens linked to smoking, biomass fuel exposure, air pollution, and population aging, with Japan, South Korea, and Australia showing stronger adoption of guideline-based maintenance care than many lower-access settings.

Latin America shows growing demand as Brazil and Mexico strengthen diagnosis and chronic disease programs, but affordability, access to spirometry, and consistent availability of maintenance inhalers remain uneven. In the Middle East and Africa, development is tied to urban air quality, tobacco use, occupational exposure, specialty care availability, and public-sector procurement, with GCC countries showing faster uptake of advanced therapies than many African markets where underdiagnosis and limited respiratory infrastructure remain major constraints.

Key Group Insights

Within ASEAN, COPD treatment demand is influenced by tobacco exposure, urban pollution, biomass fuel use, and variable access to spirometry, creating opportunities for affordable inhalers, physician education, smoking cessation, and digital screening. GCC countries are comparatively well positioned for advanced COPD therapeutics because of higher healthcare spending, specialized hospitals, national health transformation programs, and growing chronic respiratory disease management initiatives.

The European Union offers a mature but highly regulated environment where comparative effectiveness, inhaler sustainability, pharmacoeconomic evidence, and payer outcomes are central to market access. BRICS countries represent a large-volume access opportunity, particularly China and India, where disease burden is substantial and broader diagnosis can shift treatment from rescue medication toward maintenance therapy, while Brazil, Russia, and South Africa add important demand shaped by public procurement and access variability.

G7 markets are innovation-led, with strong adoption of evidence-backed triple therapy, biologics for defined populations, and digital respiratory management supported by specialist networks and real-world evidence infrastructure. NATO countries overlap with many high-income respiratory markets, but demand patterns vary by national healthcare structures, smoking prevalence, military and veteran respiratory health needs, occupational exposure, air quality policies, and reimbursement rules.

Key Country Insights

The United States leads in COPD therapeutic innovation, specialist prescribing, and uptake of newly approved mechanisms, supported by FDA pathways, extensive clinical trial infrastructure, and high use of combination inhaled therapies in appropriate patients. Canada follows evidence-based treatment pathways with strong emphasis on smoking cessation, vaccination, pulmonary rehabilitation, and chronic disease management, while Mexico and Brazil present access-led expansion potential through broader diagnosis, public procurement, and availability of affordable maintenance inhalers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central markets for inhaled combination therapies, guideline implementation, and real-world evidence generation. Germany and France are particularly important for market access assessment and comparative value evaluation, while the United Kingdom continues to prioritize integrated respiratory care, prevention, and early diagnosis. Russia retains significant COPD treatment demand but faces access variability linked to healthcare funding, regional delivery differences, and supply conditions.

China and India represent the largest long-term patient pools, driven by smoking, air pollution, biomass exposure, occupational risk, and aging demographics, though underdiagnosis and limited spirometry access remain critical barriers. Japan, Australia, and South Korea show strong adoption of guideline-based care, high physician engagement, and favorable conditions for advanced inhaler technologies, digital monitoring, pulmonary rehabilitation, and selected biologic use in appropriate patient segments.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and services that demonstrate measurable reductions in moderate-to-severe exacerbations, hospital admissions, rescue medication use, and total cost of care. Evidence generation should include diverse COPD populations, blood eosinophil-defined subgroups, comorbid cardiovascular disease, real-world adherence, inhaler technique, health-related quality of life, and device preference, as payers increasingly expect outcomes beyond lung function improvement.

Organizations should also invest in patient-friendly inhaler design, adherence support, digital monitoring, clinician education, and integrated care models to address persistent gaps in technique and persistence. Commercial strategies should be region-specific: premium innovation and real-world evidence in G7 and EU markets, access partnerships in BRICS and ASEAN, and public-sector engagement in Latin America, the Middle East, and Africa.

Research Methodology

This executive summary is built on a structured review of verified public-domain evidence, including WHO respiratory disease statistics, GOLD strategy recommendations, regulatory approvals from agencies such as the FDA and EMA, peer-reviewed COPD literature, and recognized public health sources including CDC, national health agencies, and respiratory societies.

The methodology combines disease-burden assessment, therapy-class mapping, regulatory tracking, regional healthcare analysis, and market-access interpretation. Insights were validated by cross-checking clinical guidelines, approval labels, epidemiological indicators, and health-system characteristics to ensure that conclusions remain evidence-led, clinically grounded, and commercially relevant without relying on market sizing or forecasting.

Conclusion

The COPD therapeutics landscape is transitioning from a largely inhaler-centered category into a more segmented, outcome-driven ecosystem. Long-acting bronchodilators and inhaled corticosteroid combinations remain foundational, but biologics, novel anti-inflammatory agents, digital monitoring, and AI-enabled care pathways are redefining how high-risk patients are identified and managed.

Future leadership will depend on the ability to pair clinical differentiation with access, adherence, and real-world value. Organizations that align innovation with guideline-based phenotyping, payer-recognized outcomes, validated digital support, and regional affordability needs will be best positioned to improve COPD treatment worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Product
7.1. Introduction
7.2. Antibiotics
7.3. Bronchodilators
7.4. Combination Products
7.5. Corticosteroids
7.6. Mucolytics
8. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Disease Severity
8.1. Introduction
8.2. Stage 1 (Mild)
8.3. Stage 2 (Moderate)
8.4. Stage 3 (Severe)
8.5. Stage 4 (Very Severe)
9. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.2.1. Dry Powder Inhaler
9.2.2. Metered Dose Inhaler
9.2.3. Nebulizer
9.3. Injectable
9.4. Oral
10. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Molecule Type
10.1. Introduction
10.2. Small Molecules
10.3. Biologics
11. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
12. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Chronic Obstructive Pulmonary Disease Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Homecare
13.4. Hospitals
14. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Almirall S.A.
18.3. Amgen Inc.
18.4. Amneal Pharmaceuticals, Inc.
18.5. Apotex Inc.
18.6. AstraZeneca plc
18.7. Aurobindo Pharma Ltd.
18.8. Boehringer Ingelheim International GmbH
18.9. Chiesi Farmaceutici S.p.A
18.10. Cipla Limited
18.11. CSL Limited
18.12. Dr. Reddy's Laboratories Limited
18.13. GlaxoSmithKline plc
18.14. Glenmark Pharmaceuticals Ltd.
18.15. Lupin Ltd.
18.16. Merck & Co., Inc.
18.17. Mylan N.V.
18.18. Novartis AG
18.19. Orion Corporation
18.20. Sandoz International GmbH
18.21. Sawai Pharmaceutical Co., Ltd.
18.22. Sun Pharmaceutical Industries Ltd
18.23. Takeda Pharmaceutical Company Limited
18.24. Teva Pharmaceutical Industries Ltd
18.25. Theravance Biopharma, Inc.
18.26. Verona Pharma plc
18.27. Yuhan Corporation
18.28. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MUCOLYTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MUCOLYTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MUCOLYTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL STAGE 1 (MILD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL STAGE 1 (MILD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL STAGE 1 (MILD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL STAGE 2 (MODERATE) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL STAGE 2 (MODERATE) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL STAGE 2 (MODERATE) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL STAGE 3 (SEVERE) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL STAGE 3 (SEVERE) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL STAGE 3 (SEVERE) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL STAGE 4 (VERY SEVERE) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL STAGE 4 (VERY SEVERE) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL STAGE 4 (VERY SEVERE) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 115. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 116. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 118. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 119. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 120. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 121. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 133. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 134. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 136. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 137. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 138. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 139. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 143. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 144. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 146. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 147. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 148. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 152. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 153. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 155. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 156. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 157. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 170. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 171. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 173. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 174. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 179. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 180. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 182. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 183. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 184. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 185. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 188. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 189. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 191. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 192. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 193. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 194. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 207. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 208. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 210. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 211. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 212. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 216. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 217. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 219. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 220. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 221. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 228. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 229. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 230. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 243. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 244. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 246. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 247. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 252. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 253. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 255. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 256. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 257. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 264. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 270. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 271. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 273. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 274. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 275. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 279. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 280. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 282. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 283. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 284. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 288. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 289. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2017-2032 (USD MILLION)
TABLE 291. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 292. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A
  • Cipla Limited
  • CSL Limited
  • Dr. Reddy's Laboratories Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Sandoz International GmbH
  • Sawai Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Theravance Biopharma, Inc.
  • Verona Pharma plc
  • Yuhan Corporation
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 25.16 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.16 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Treatment Market - Global Forecast 2026-2032 - Product Image

Chronic Obstructive Pulmonary Disease Treatment Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Drugs Market 2026-2030 - Product Image

Chronic Obstructive Pulmonary Disease Drugs Market 2026-2030

  • Report
  • 306 Pages
  • Global
From

About the Chronic Obstructive Pulmonary Disease Drug Market

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions. The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.